Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stuart Elborn

Showing results (31-40 of 290) with videos related to

Pageof 29
Sort By:
The European Respiratory Journal|August 5, 2017
Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysisPierre-Régis Burgel, Gil Bellis, J Stuart Elborn
Respiratory Medicine|October 11, 2014
Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questionsCharles S Haworth, Diana Bilton, J Stuart Elborn
Thorax|July 1, 2008
Obesity and the respiratory physicianFionnuala Crummy, Matthew T Naughton, J Stuart Elborn
European Journal of Internal Medicine|February 14, 2004
Bronchiectasis in secondary care: a comprehensive profile of a neglected diseaseMartin G. Kelly, S. Murphy, J. Stuart Elborn
Plos One|March 14, 2012
Comparison of nasal and bronchial epithelial cells obtained from patients with COPDDavid M Comer, J Stuart Elborn, Madeleine Ennis
Thorax|October 29, 2015
Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and BarryJ Stuart Elborn, Bonnie Ramsey, Claire Wainwright, et al.
The New England Journal of Medicine|October 29, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey
Lancet (London, England)|August 26, 2014
Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosisLaura J Sherrard, Michael M Tunney, J Stuart Elborn
The New England Journal of Medicine|March 26, 2026
Hypertonic Saline or Carbocisteine in Bronchiectasis. ReplyJudy M Bradley, Daniel F McAuley, J Stuart Elborn
Chest|August 13, 2011
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosaMichael D Parkins, Jacqueline C Rendall, J Stuart Elborn
Pageof 29

Showing results (31-40 of 290) with videos related to

Sort By:
Pageof 29
The European Respiratory Journal|August 5, 2017
Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysisPierre-Régis Burgel, Gil Bellis, J Stuart Elborn
Respiratory Medicine|October 11, 2014
Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questionsCharles S Haworth, Diana Bilton, J Stuart Elborn
Thorax|July 1, 2008
Obesity and the respiratory physicianFionnuala Crummy, Matthew T Naughton, J Stuart Elborn
European Journal of Internal Medicine|February 14, 2004
Bronchiectasis in secondary care: a comprehensive profile of a neglected diseaseMartin G. Kelly, S. Murphy, J. Stuart Elborn
Plos One|March 14, 2012
Comparison of nasal and bronchial epithelial cells obtained from patients with COPDDavid M Comer, J Stuart Elborn, Madeleine Ennis
Thorax|October 29, 2015
Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and BarryJ Stuart Elborn, Bonnie Ramsey, Claire Wainwright, et al.
The New England Journal of Medicine|October 29, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey
Lancet (London, England)|August 26, 2014
Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosisLaura J Sherrard, Michael M Tunney, J Stuart Elborn
The New England Journal of Medicine|March 26, 2026
Hypertonic Saline or Carbocisteine in Bronchiectasis. ReplyJudy M Bradley, Daniel F McAuley, J Stuart Elborn
Chest|August 13, 2011
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosaMichael D Parkins, Jacqueline C Rendall, J Stuart Elborn
Pageof 29